What Happened?
Shares of medical lens company STAAR Surgical (NASDAQ: STAA) jumped 3.1% in the morning session after the stock gained ground amid broader positive market sentiment as investors awaited a busy week of corporate earnings.
With no major company-specific news released, the developer of implantable lenses for the eye appeared to be benefiting from a wider market rally. Investors were expecting a heavy slate of earnings reports from major companies during the week. Notably, the earnings season got off to a strong start: More than 85% of the S&P 500 stocks that reported earnings exceeded expectations, according to FactSet data. This robust performance fueled positive sentiment, suggesting that corporate profitability remained resilient despite ongoing economic uncertainties.
After the initial pop the shares cooled down to $17.61, up 1.5% from previous close.
Is now the time to buy STAAR Surgical? Access our full analysis report here, it’s free.
What Is The Market Telling Us
STAAR Surgical’s shares are very volatile and have had 29 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The previous big move we wrote about was 10 days ago when the stock dropped 3.4% on the news that the U.S. administration announced a sharp escalation in trade tensions by threatening new tariffs on Canada.
The wider market sentiment turned negative after the White House announced plans to impose a 35% tariff on Canadian imports, sparking renewed fears of a trade war. This news prompted a sell-off across major U.S. indexes, including the S&P 500 and the Dow Jones Industrial Average, as investors grew concerned about the potential economic impact of escalating protectionist policies. The healthcare sector is especially vulnerable to such tensions due to its deeply integrated supply chains with Canada for pharmaceuticals and medical devices, meaning increased costs and potential disruptions. Additionally, ongoing U.S. policy headwinds aimed at lowering drug prices and specific corporate challenges, like those faced by UnitedHealth Group, further compounded the sector's decline. As a result, the Health Care SPDR ETF (XLV) fell 1.0%, underperforming even as major indices pared some losses.
STAAR Surgical is down 26.9% since the beginning of the year, and at $17.61 per share, it is trading 58.9% below its 52-week high of $42.89 from July 2024. Investors who bought $1,000 worth of STAAR Surgical’s shares 5 years ago would now be looking at an investment worth $312.03.
Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link.
